Health Economics›Classical Hodgkin lymphoma pediatric›Upfront therapy high-risk

Upfront therapy high-risk

Classical Hodgkin lymphoma pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bv-AVEPC Variant #01	—	R 88 301	21d	—	—	~5	~R 441 505 indirect	—
ABVE-PC Partial	—	R 7 248	21d	—	—	~5	~R 19 061 indirect	—

2 of 2 regimens shown